secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0001104659-25-032189
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma approves 1-for-35 reverse ADS split effective April 9 to meet Nasdaq bid price rule
--------------------------------------------------------------------------------

- ADS ratio changes from 1 ADS = 1 ordinary share to 1 ADS = 35 ordinary shares, effective April 9, 2025.
- Reverse split aims to increase ADS price to comply with Nasdaq's $1.00 minimum bid price requirement.
- Ordinary shares unaffected; new CUSIP for ADS will be 74907L409; ticker QNRX unchanged.
- Holders of DRS and DTC ADSs need no action; certificated holders must surrender every 35 old ADSs for 1 new ADS.
- Company cautions that it cannot guarantee the ratio change will achieve or maintain Nasdaq compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925032189/0001104659-25-032189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925032189/tm2511590d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-032189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer